- Home
- BCLI vs BTAI Comparison
BCLI vs BTAI Comparison
Compare BCLI & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCLI
- BTAI
- Stock Information
- Founded
- BCLI 2000
- BTAI 2017
- Country
- BCLI United States
- BTAI United States
- Employees
- BCLI N/A
- BTAI N/A
- Industry
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- BCLI Health Care
- BTAI Health Care
- Exchange
- BCLI Nasdaq
- BTAI Nasdaq
- Market Cap
- BCLI 9.8M
- BTAI 8.3M
- IPO Year
- BCLI N/A
- BTAI 2018
- Fundamental
- Price
- BCLI $1.16
- BTAI $1.99
- Analyst Decision
- BCLI Strong Buy
- BTAI Buy
- Analyst Count
- BCLI 1
- BTAI 5
- Target Price
- BCLI $30.00
- BTAI $34.60
- AVG Volume (30 Days)
- BCLI 412.8K
- BTAI 289.2K
- Earning Date
- BCLI 08-13-2025
- BTAI 08-05-2025
- Dividend Yield
- BCLI N/A
- BTAI N/A
- EPS Growth
- BCLI N/A
- BTAI N/A
- EPS
- BCLI N/A
- BTAI N/A
- Revenue
- BCLI N/A
- BTAI $1,852,000.00
- Revenue This Year
- BCLI N/A
- BTAI $5.03
- Revenue Next Year
- BCLI N/A
- BTAI $291.01
- P/E Ratio
- BCLI N/A
- BTAI N/A
- Revenue Growth
- BCLI N/A
- BTAI 5.47
- 52 Week Low
- BCLI $0.72
- BTAI $1.17
- 52 Week High
- BCLI $6.45
- BTAI $21.92
- Technical
- Relative Strength Index (RSI)
- BCLI 49.98
- BTAI 56.97
- Support Level
- BCLI $1.02
- BTAI $1.69
- Resistance Level
- BCLI $1.32
- BTAI $2.08
- Average True Range (ATR)
- BCLI 0.09
- BTAI 0.20
- MACD
- BCLI -0.00
- BTAI 0.02
- Stochastic Oscillator
- BCLI 46.67
- BTAI 61.84
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.